Uploaded October 2026 | Updated November 2026, 1 day ago
Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are rapidly increasing in prevalence, driven by rising rates of obesity, insulin resistance, and other metabolic risk factors. Faculty will review the physiological roles of glucagon and incretin receptor signaling and explain how emerging therapies modulate these pathways to improve liver and cardiometabolic outcomes. Join this program to stay current and gain practical guidance to help improve the care of patients with MASLD/MASH.
Multiple CE credit types available: bit.ly/MASLD_MASH
Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are rapidly increasing in prevalence, driven by rising rates of obesity, insulin resistance, and other metabolic risk factors. Faculty will review the physiological roles of glucagon and incretin receptor signaling and explain how emerging therapies modulate these pathways to improve liver and cardiometabolic outcomes. Join this program to stay current and gain practical guidance to help improve the care of patients with MASLD/MASH.
Multiple CE credit types available: bit.ly/MASLD_MASH










